Skip to main content
Premium Trial:

Request an Annual Quote

Deltagen CEO Follows President Out the Door

NEW YORK, Feb. 13 - Just three weeks after announcing that its president had left, Deltagen said today that its CEO, William Matthews, had resigned.


Matthews, a co-founder of Deltagen, has served as CEO since 1998.


The office of board chairman Constantine Anagnostopoulos will manage the company until it finds a new CEO, Deltagen said.

The company has been publicly searching for a new CEO since November, after changing course from drug discovery to tools and services, but Matthews was directing day-to-day operations of the transgenic technology company, along with Anagnostopoulos and chief financial officer Richard Hawkins.


Matthews departure is the latest sign that the company, like others in the sector, has been struggling to survive. On Jan. 21, president and chief operating officer Michael Sember left. At the time, GenomeWeb reported that the company had reduced its headcount to 200 and made plans to cut loose its proteomics subsidiary and its Strasbourg, FranceR&D center. In December, the company received a Nasdaq warning letter that it must bring its stock price above that benchmark before March 19 or risk being delisted.

The Scan

Ancient Greek Army Ancestry Highlights Mercenary Role in Historical Migrations

By profiling genomic patterns in 5th century samples from in and around Himera, researchers saw diverse ancestry in Greek army representatives in the region, as they report in PNAS.

Estonian Biobank Team Digs into Results Return Strategies, Experiences

Researchers in the European Journal of Human Genetics outline a procedure developed for individual return of results for the population biobank, along with participant experiences conveyed in survey data.

Rare Recessive Disease Insights Found in Individual Genomes

Researchers predict in Genome Medicine cross-population deletions and autosomal recessive disease impacts by analyzing recurrent nonallelic homologous recombination-related deletions.

Genetic Tests Lead to Potential Prognostic Variants in Dutch Children With Dilated Cardiomyopathy

Researchers in Circulation: Genomic and Precision Medicine found that the presence of pathogenic or likely pathogenic variants was linked to increased risk of death and poorer outcomes in children with pediatric dilated cardiomyopathy.